source
- Parkinson's drug pipeline diversifies as firms seek disease-modifying therapiesSeveral pharmaceutical companies are shifting away from the traditional alpha-synuclein antibody strategy and exploring alternative mechanisms to treat Parkinson's disease. AC Immune is highlighted…
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…